News >

Brentjens Highlights BCMA, Next Steps With CAR T-Cell Therapy

Danielle Bucco
Published: Thursday, Mar 22, 2018

Renier J. Brentjens, MD

Renier J. Brentjens, MD
CD19 has shown great success as a target for chimeric antigen receptor (CAR) T-cell therapy in both acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Now, the B-cell maturation antigen (BCMA) has emerged as another promising target, according to Renier J. Brentjens, MD, PhD.

, Brentjens, an associate professor, and chief of the Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discussed the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.

OncLive: Can you discuss other targets being investigated in addition to CD19 for CAR T-cell therapy?

Brentjens: There has been a significant amount of success targeting CD19 on B-cell cancers. In fact, there are 2 drugs that are now commercially available, one from Novartis and one from Gilead. Both are targeting tumor cells that express CD19, particularly in children and young adults with ALL, as well as adults with DLBCL. The question is whether this is the end of the road or if these genetically modified CAR T cells are eventually going to be applied to other cancers or other types of targets.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x